Enasidenib
Idhifa
Near Add Your Location
Accepting patients
Azacitidine and Enasidenib for IDH-2 Mutations
Targeted Therapy With the IDH2-Inhibitor Enasidenib (AG221) for High-Risk IDH2-Mutant Myelodysplastic Syndrome
- IDH2 Inhibitor
- Phase 2
Accepting patients
MyeloMATCH Master Protocol
Master Screening and Reassessment Protocol (MSRP) for the NCI MyeloMATCH Clinical Trials
- Genetic Sequencing
- Phase 2
Showing 1-2 of 2